Advanced Filters
noise

mild-cognitive-impairment Clinical Trials

A listing of mild-cognitive-impairment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 707 clinical trials
S Stephanie Neaves, MCRC

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history …

55 years of age All Phase 2
S Sarah Bohlman, MSL

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

The Brain Energy for Amyloid Transformation in AD (Alzheimer's disease) or BEAT-AD study will compare the effects of a ketogenic low-carbohydrate diet and a low-fat diet in adults with mild cognitive impairment. The data collected will help determine whether diet interventions induce changes in cognitive function, cerebral blood flow, and …

55 - 85 years of age All Phase N/A
A Alexander Pantel, MD

Music Therapy for Patients With Alzheimer's Disease

This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD). 60 patients with MCI or mild dementia due to AD will receive two …

18 - 89 years of age All Phase N/A
M Mitzi Gonzales, PhD

Rapamycin - Effects on Alzheimer's and Cognitive Health

This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).

55 - 89 years of age All Phase 2

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

30 - 74 years of age All Phase 1
N Nick Bienko, MA

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment. The main question[s] it aims to answer are: Does the hormone response to acute stress predict the degree of cognitive impairment following acute stress? …

60 years of age All Phase N/A
M Minqian Gao, B.sc

A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids

Background Deafness is one of the nine potentially modifiable risk factors for dementia simulated by the Lancet dementia Prevention, intervention and Care Committee in 2017. Some studies have found that the risk factors of dementia in deafness system, with the increase of the degree of deafness, the risk of cognitive …

60 - 85 years of age All Phase N/A
A Amala Soumyanath, PhD

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.

60 - 85 years of age All Phase 1
A Alyssa M Lanzi, Ph.D.

Promoting Independence With Compensatory Cognitive Rehabilitation

Alzheimer's disease (AD) is one of the leading causes of disability in older adults. Because pharmacological approaches do not seem to prevent or slow the disease, clinicians need non-pharmacological interventions that might help people with AD remain independent for as long as possible. This study aims to evaluate the effects …

60 - 90 years of age All Phase N/A
M Martha Forloines, PhD

Senicapoc in Alzheimer's Disease

Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans …

55 - 85 years of age All Phase 2

Simplify language using AI